Middle East And Africa Blood Plasma And Plasma Derived Medicinal Products Market
시장 규모 (USD 10억)
연평균 성장률 :
% 
USD
1.34 Billion
USD
2.17 Billion
2024
2032
 예측 기간 |
2025 –2032 |
 시장 규모(기준 연도) |
USD 1.34 Billion |
 시장 규모(예측 연도) |
USD 2.17 Billion |
 연평균 성장률 |
% |
| 주요 시장 플레이어 |
|
중동 및 아프리카 혈장 및 혈장 유래 의약품 시장 세분화, 제품별( 면역글로불린 , 응고 인자(출혈 질환용), 알부민 (혈장 용적 확장제), 프로테아제 억제제(유전적 결핍용), 단일클론 항체(혈장 세포에서 유래), 기타 혈장 유래 단백질), 응용 분야(면역학, 혈액학, 중환자 치료, 신경학, 폐의학, 혈액종양학 , 류마티스학 및 기타 응용 분야), 처리 기술(이온 교환 크로마토그래피, 친화성 크로마토그래피, 극저온 침전, 초 미세 여과 및 미세 여과), 모드(현대 및 전통적 혈장 분획), 최종 사용자(병원 및 진료소, 연구소, 학술 기관 및 기타), 유통 채널(직접 입찰, 제3자 유통업체 및 기타) - 산업 동향 및 예측 2032년까지
혈장 및 혈장 유래 의약품 시장 규모
- 중동 및 아프리카 혈장 및 혈장 유래 의약품 시장은 2024년에 13억 4,000만 달러 규모로 평가되었으며, 예측 기간 동안 6.25%의 CAGR 로 2032년까지 21억 6,800만 달러에 도달할 것으로 예상됩니다 .
- 시장 성장은 주로 희귀 및 만성 질환의 유병률 증가에 의해 촉진됩니다.
- 더욱이, 혈장 및 혈장 유래 의약품의 혈장 분획 기술 발전이 두드러지고 있습니다. 이러한 융합 요인들은 혈장 및 혈장 유래 의약품 솔루션의 도입을 가속화하여 업계 성장을 크게 촉진하고 있습니다.
혈장 및 혈장 유래 의약품 시장 분석
- 혈우병, 면역결핍 장애, 자가면역 질환과 같은 질환을 치료하는 데 있어 혈장 유래 치료법에 대한 수요 증가로 시장이 확대되고 있으며, 이는 수혈 의학에 대한 인식이 높아지고 발전함에 따라 뒷받침되고 있습니다.
- 혈액 수집, 분획 및 냉장 물류 분야의 기술 발전으로 제품 품질과 유통 기한이 향상되어 전 세계 병원, 외상 센터 및 진단 실험실에서 더 폭넓은 도입이 촉진되고 있습니다.
- 남아프리카공화국은 개선된 의료 인프라, 혈장 치료제 수요 증가, 정부 지원 증가, 만성 및 감염성 질환 유병률 증가로 인해 혈장 및 혈장 유래 의약품 시장 점유율 29.62%를 차지할 것으로 예상됩니다.
- 남아프리카공화국은 의료 투자 증가, 만성 및 감염성 질환 유병률 증가, 진단 시설 개선, 혈액 안전에 대한 인식 제고, 혈장 치료 접근성 및 인프라 강화를 위한 정부 이니셔티브로 인해 혈장 및 혈장 유래 의약품 시장에서 가장 빠르게 성장하는 지역이 될 것으로 예상됩니다.
- 면역글로불린 부문은 표적 치료에 대한 수요 증가, 정제 기술 개선, 면역 관련 질환 유병률 증가로 인해 2025년에 42.41%의 점유율로 혈장 및 혈장 유래 의약품 시장을 지배할 것으로 예상됩니다.
보고서 범위 및 혈장 및 혈장 유래 의약품 시장 세분화
|
속성 |
혈장 및 혈장 유래 의약품 주요 시장 통찰력 |
|
다루는 세그먼트 |
|
|
포함 국가 |
중동 및 아프리카
|
|
주요 시장 참여자 |
|
|
시장 기회 |
|
|
부가가치 데이터 정보 세트 |
Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 적용 범위, 주요 기업 등 시장 시나리오에 대한 통찰력 외에도 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석, 규제 프레임워크가 포함됩니다. |
혈장 및 혈장 유래 의약품 시장 동향
“희귀 및 만성 질환 유병률 증가”
- 혈장 및 혈장 유래 의약품 시장의 주요 원동력은 진단 기술의 발전과 의료 서비스 제공자 및 환자의 인식 제고로 인해 전 세계적으로 희귀 및 만성 질환의 유병률이 증가하고 있다는 것입니다.
- 예를 들어, 2025년 4월 미국 질병통제예방센터(CDC) 데이터에 따르면 미국 성인의 76.4%가 최소 한 가지 만성 질환을 앓고 있었고, 51.4%는 여러 질환을 앓고 있었습니다. 젊은 성인에서도 관찰되는 이러한 증가 추세는 특히 혈우병, 원발성 면역결핍증, 폰 빌레브란트병과 같은 질환에 대한 평생 치료에 대한 수요를 증가시켰습니다.
- 면역글로불린, 응고인자, 알부민과 같은 혈장 유래 치료제는 이러한 평생 질환을 관리하는 데 필수적입니다. 원발성 면역결핍증 환자는 면역 지원을 위해 IVIG에 의존하는 반면, 혈우병 환자는 출혈을 예방하기 위해 정기적인 응고인자 주입이 필요합니다.
- 전 세계 인구 고령화로 인해 이러한 추세가 더욱 가속화되고 있으며, 노인들은 간경변, 다발성 골수종, 염증성 질환과 같은 질환에 점점 더 많이 시달리고 있으며 이러한 질환들은 모두 혈장 유래 개입을 필요로 합니다.
- 2025년 3월, PMC에 발표된 연구는 희귀 질환, 특히 소아 환자의 전 세계적인 부담이 얼마나 큰지를 강조했습니다. 유전체 의학과 희귀의약품 개발의 발전에도 불구하고, 진단 지연과 제한된 치료 옵션은 여전히 남아 있어 다학제적이고 지속적인 치료의 필요성을 강조합니다.
- 안전하고 효과적이며 고품질의 혈장 유래 치료법에 대한 수요 증가는 혈장 및 혈장 유래 의약품 시장을 주도하는 핵심 요인입니다. 이러한 제품은 평생 질병을 관리하고 충족되지 않은 의료적 요구 사항을 해결하는 데 중요한 역할을 하기 때문입니다.
혈장 및 혈장 유래 의약품 시장 동향
운전사
“노인 인구 확대”
- 혈장 및 혈장 유래 의약품에 대한 수요 증가는 면역 체계 장애, 신경 질환, 간 합병증 및 면역글로불린, 알부민, 응고 인자를 포함한 혈장 기반 치료법이 필요한 혈액 관련 문제와 같은 만성 및 퇴행성 질환에 더 취약한 고령화된 세계 인구에 의해 크게 촉진됩니다.
- 예를 들어, 2025년 3월, PMC에 게재된 연구에서는 2010년부터 2024년까지 미국 국립 입원 환자 표본(NIS) 데이터를 분석하여 고령 인구의 급격한 증가로 인해 입원, 입원 기간 연장, 그리고 재입원율이 크게 증가한 것으로 나타났습니다. 만성 질환과 복합 질환으로 인한 이러한 추세는 의료 시스템의 부담 증가와 그에 따른 혈장 유래 치료제 수요 증가를 보여줍니다.
- 나이가 들면서 면역 체계가 약화되어 감염 및 자가면역 질환에 대한 취약성이 증가합니다. 면역글로불린 요법은 만성 염증성 탈수초성 다발신경병증(CIDP)과 같은 질환 치료에 자주 사용되는 반면, 알부민은 고령 환자의 수술 및 중환자 치료 시 체액 균형 조절에 필수적입니다.
- 고령 인구 비율이 높은 국가에서는 PDMP(혈장분리막) 소비가 지속적으로 증가하고 있습니다. 이러한 인구학적 추세는 국가 의료 시스템에 중단 없는 공급망과 충분한 혈장 수집을 보장해야 하는 엄청난 부담을 안겨줍니다.
- 세계보건기구(WHO) 추산에 따르면 2023년 11억 명이었던 전 세계 60세 이상 인구가 2050년에는 21억 명으로 증가할 것으로 예상됨에 따라 노인 의료의 중요성이 더욱 강조됩니다. 이러한 인구학적 변화는 장기적인 치료 지원의 필요성을 증폭시킬 뿐만 아니라, 노인 인구를 PDMP의 핵심적이고 지속적인 시장 부문으로 자리매김하게 합니다.
제지/도전
“ 고비용 및 복잡한 제조 공정 ”
- 혈장 및 혈장 유래 의약품 제조에 따르는 높은 비용과 복잡성은 시장 확장에 큰 걸림돌이 됩니다. 이 공정은 엄격한 혈장 채취 프로토콜, 광범위한 병원균 검사, 그리고 무균 및 GMP 준수 환경에서의 다단계 분획을 요구하기 때문에 생산에 막대한 자원과 시간이 소요될 수 있습니다.
- 예를 들어, Aykon Biosciences의 상세 분석에 따르면 혈장 유래 치료제와 같은 복잡한 생물학적 제제 제조는 값비싼 원자재, 숙련된 인력 요구, 그리고 점점 더 엄격해지는 규제 준수 요구로 인해 비용 압박이 증가하고 있습니다. 전문화되고 개인화된 치료법으로의 전환은 비용을 더욱 증가시켜 첨단 기술과 엄격한 품질 보증 시스템을 필요로 합니다.
- 또한, PDMP의 제조 주기는 최대 12개월까지 길어질 수 있으며, 공정 전반에 걸쳐 보관 및 운송을 위한 콜드체인 물류가 필요합니다. 이러한 요인들은 자본 및 운영 비용을 크게 증가시켜 확장성을 제한하고 소규모 업체와 개발도상국의 시장 참여를 저해합니다.
- 생산 비용 집약적인 특성 또한 최종 제품 가격 상승에 영향을 미쳐, 특히 의료 예산이 부족한 저소득 및 중소득 국가에서 접근성과 구매력을 저하시킵니다. 이러한 재정적 부담은 증가하는 글로벌 수요를 충족하는 데 어려움을 야기하여, 전 세계적으로 PDMP의 광범위한 도입을 저해합니다.
- 지속적인 기술 혁신을 통해 비용 효율성이 점진적으로 향상될 수 있지만, 현재의 높은 생산 및 가공 비용은 여전히 주요 제약 요소로 남아 있습니다. 제조 기술 개선, 공여 인프라 확대, 그리고 적극적인 공중 보건 기금 지원을 통해 이러한 과제를 해결하는 것은 더 넓은 시장 접근성과 공평한 치료 보장을 확보하는 데 필수적입니다.
혈장 및 혈장 유래 의약품 시장 범위
시장은 제품, 응용 분야, 처리 기술, 모드, 최종 사용자 및 유통 채널을 기준으로 세분화됩니다.
- 제품별
제품별로 시장은 면역글로불린, 응고인자(출혈 질환 치료), 알부민(혈장량 증가제), 프로테아제 억제제(유전적 결핍 치료), 단일클론 항체(혈장 세포 유래) 및 기타 혈장 유래 단백질로 세분화됩니다. 2025년에는 면역글로불린 부문이 면역결핍 진단 증가, 자가면역 질환, 그리고 정맥 면역글로불린(IVIG) 사용 증가에 힘입어 42.41%의 시장 점유율을 기록하며 시장을 주도할 것으로 예상됩니다.
응고 인자(출혈성 질환 치료) 부문은 혈우병 환자 증가, 진단 접근성 향상, 정부 지원, 재조합 및 혈장 유래 치료법 사용 확대에 힘입어 2025년부터 2032년까지 6.41%의 가장 빠른 성장률을 보일 것으로 예상됩니다.
- 응용 프로그램별
응용 분야별로 시장은 면역학, 혈액학, 중환자 치료, 신경학, 폐의학, 혈액종양학, 류마티스학 및 기타 분야로 세분화됩니다. 면역학 분야는 2025년 시장 매출 점유율이 가장 높았는데, 이는 원발성 면역결핍증 및 자가면역 질환 치료에 널리 사용되고 있으며, 정맥주사 면역글로불린(IVIG)에 대한 전 세계 수요 증가에 힘입은 것입니다.
면역학 분야는 2025년부터 2032년까지 가장 빠른 CAGR을 기록할 것으로 예상되며, 이는 자가면역 질환의 유병률 증가, 인구 고령화, 면역글로불린 치료법의 임상 적용 확대에 힘입은 것입니다.
- 가공 기술로
처리 기술을 기준으로 시장은 이온 교환 크로마토그래피, 친화성 크로마토그래피, 동결침전, 한외여과, 정밀여과로 구분됩니다. 이온 교환 크로마토그래피 부문은 면역글로불린, 알부민, 응고 인자와 같은 혈장 단백질 정제에 있어 높은 효율, 확장성, 그리고 효과성을 바탕으로 2025년 시장 매출 점유율 1위를 차지했습니다.
친화성 크로마토그래피 부문은 2025년부터 2032년까지 가장 빠른 CAGR을 기록할 것으로 예상되며, 높은 특이성, 표적 단백질 분리 능력, 고급 생물학적 정제 분야에서의 채택 증가로 선호됩니다.
- 모드별
시장은 방식에 따라 현대식 혈장 분획법과 전통식 혈장 분획법으로 구분됩니다. 현대식 혈장 분획법은 첨단 처리 기술, 더 높은 제품 순도, 향상된 안전성 프로파일, 그리고 재조합 및 고수율 혈장 유래 치료법의 도입 증가를 주도하며 2025년 시장 매출 점유율 1위를 차지했습니다.
현대 분야는 정제 기술의 혁신, 더 안전한 생물학 제제에 대한 수요 증가, 차세대 플라즈마 처리 기술에 대한 투자 증가로 인해 2025년부터 2032년까지 가장 빠른 CAGR을 보일 것으로 예상됩니다.
- 최종 사용자별
최종 사용자 기준으로 시장은 병원 및 진료소, 연구소, 학술 기관 등으로 세분화됩니다. 병원 및 진료소 부문은 2025년에 가장 큰 시장 매출 점유율을 차지했는데, 이는 높은 환자 수, 전문 치료 접근성, 만성 질환 치료 증가, 그리고 첨단 혈장 유래 치료법 접근성 덕분입니다.
병원 및 진료소 부문도 2025년부터 2032년까지 가장 빠른 CAGR을 기록할 것으로 예상되며, 이는 의료 인프라 확장, 입원 환자 증가, 복잡한 질환에 대한 플라스마 치료법 의존도 증가에 힘입은 것입니다.
- 유통 채널별
유통 채널을 기준으로 시장은 직접 입찰, 제3자 유통업체, 그리고 기타 업체로 구분됩니다. 직접 입찰 부문은 정부 기관의 대량 구매, 비용 효율성, 안정적인 공급망, 그리고 혈장 유래 의약품에 대한 공공 부문 투자 증가에 힘입어 2025년 시장 매출 점유율이 가장 높았습니다.
직접 입찰 부문은 정부 의료 프로그램 확대, 중앙 조달 정책 강화, 비용 효율적인 대규모 혈장 치료 유통에 대한 수요 증가에 힘입어 2025년부터 2032년까지 가장 빠른 CAGR을 기록할 것으로 예상됩니다.
혈장 및 혈장 유래 의약품 시장 지역 분석
- 남아프리카공화국은 29.62%의 가장 큰 수익 점유율로 혈장 및 혈장 유래 의약품 시장을 지배하고 있으며, 2025년에는 첨단 의료 인프라, 희귀 및 만성 질환의 진단율 증가, 1인당 의료비 지출 증가로 인해 가장 빠른 CAGR 7.42%로 성장할 것으로 예상됩니다.
- 국가의 강력한 규제 프레임워크, 견고한 상환 시스템, Grifols, CSL Behring, Takeda와 같은 주요 시장 참여자의 존재는 혈장 수집 및 치료 유통 분야에서 중동 및 아프리카의 리더십에 기여합니다.
- 주요 경제권에서는 생물약학 R&D에 막대한 투자를 하고 있으며, 혈장 수집 네트워크를 확대하고 면역학, 혈액학, 신경학 분야에서 혈장 유래 치료법에 대한 접근성을 개선하고 있습니다.
사우디아라비아 혈장 및 혈장 유래 의약품 시장 통찰력
사우디아라비아는 2025년부터 2032년까지 중동 및 아프리카 지역에서 강력한 성장을 보일 것으로 예상됩니다. 이는 탄탄한 의료 생태계, 희귀 및 만성 질환 환자 증가, 그리고 혈장 기증을 장려하는 정부의 적극적인 정책에 기인합니다. 사우디아라비아는 수많은 혈장 수집 센터를 운영하고 있으며, PDMP(혈장분획제제) 승인도 가속화되어 치료 접근성을 높이고 시장 확대를 촉진합니다.
UAE 혈장 및 혈장 유래 의약품 시장 통찰력
UAE는 보편적 의료 시스템, 희귀 질환에 대한 인식 제고, 그리고 정부의 국내 혈장 수집 역량 강화 투자에 힘입어 2025년부터 2032년까지 이 지역에서 상당한 연평균 성장률(CAGR)을 기록할 것으로 예상됩니다. PDMP(혈장 생산 및 생산) 분야에서는 전략적 파트너십과 생물학적 제제 제조 분야의 발전이 강화되고 있습니다.
혈장 및 혈장 유래 의약품 시장 점유율
혈장 및 혈장 유래 의약품 산업은 주로 다음을 포함한 잘 확립된 회사들이 주도하고 있습니다.
- CSL(호주)
- 다케다제약 주식회사(일본)
- 그리폴스, SA(스페인)
- 옥타파마 AG(스위스)
- 케드리온(이탈리아)
- Biotest AG(독일)
- 프레제니우스 카비 AG(독일)
- 카마다제약(이스라엘)
- KM Biologics(일본)
- Reliance Life Sciences(인도)
- SK플라즈마(한국)
- Synthaverse SA(폴란드)
- VIRCHOW BIOTECH(인도)
혈장 및 혈장 유래 의약품 시장의 최신 동향
- 2024년 11월, CSL Plasma는 콜로라도주 덴버 인근 6개 미국 헌혈 센터에 첨단 Rika 혈장 헌혈 시스템 도입을 확대했습니다. Terumo Blood & Cell Technologies와 공동 개발한 이 새로운 기기는 헌혈자의 편의성, 안전성, 효율성을 향상하는 동시에 채혈 시간을 약 30% 단축했습니다.
- 2022년 12월, CSL은 호주 빅토리아주에 브로드메도우즈 혈장 분획 시설을 준공했습니다. 이 시설은 남반구 최대 규모의 혈장 곡물 처리 시설입니다. 연간 920만 리터의 혈장 환산량을 처리할 수 있는 9억 달러 규모의 이 시설은 면역 결핍, 신경 질환, 그리고 이식이나 화상과 같은 중증 질환을 치료하는 혈장 기반 치료법에 대한 전 세계 수요를 충족합니다.
- 2024년 6월, 다케다는 용량 기준 세계 최고 수준인 로스앤젤레스 혈장 분획 시설의 3천만 달러 확장을 발표했습니다. 이번 시설 확충을 통해 연간 최대 200만 리터의 생산량이 증가할 것으로 예상되며, 면역결핍 및 출혈성 질환 치료에 사용되는 혈장 유래 치료제에 대한 전 세계 수요 증가에 대응할 수 있을 것으로 기대됩니다.
- 2023년, 다케다는 일본 오사카에 약 7억 6,500만 달러를 투자하여 새로운 혈장 유래 치료제 생산 공장을 건설했습니다. 이는 기존 나리타 공장의 생산 능력을 거의 5배로 늘리는 것입니다. 이 시설은 2030년까지 완전 가동될 예정이며, 일본과 글로벌 시장 모두에 서비스를 제공할 것입니다.
- 2025년 3월 Grifols는 Inpeco와 협력하여 고급 자동화 로봇(FlexLab X), 진단 및 시약을 통합하여 수혈에서 처리량이 높고 안전하고 추적 가능한 혈액 및 혈장 검사를 위한 "미래의 실험실"을 만들었습니다. 의학 실험실은 생물학적 샘플을 분석하여 질병을 진단, 모니터링 및 연구합니다.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTLE ANALYSIS
4.1.1 POLITICAL FACTORS
4.1.2 ECONOMIC FACTORS
4.1.3 SOCIAL FACTORS
4.1.4 TECHNOLOGICAL FACTORS
4.1.5 ENVIRONMENTAL FACTORS
4.1.6 LEGAL FACTORS
4.2 PORTER’S FIVE FORCES
4.2.1 THREAT OF NEW ENTRANTS
4.2.2 BARGAINING POWER OF SUPPLIERS
4.2.3 BARGAINING POWER OF BUYERS
4.2.4 THREAT OF SUBSTITUTES
4.2.5 INDUSTRY RIVALRY
4.3 SUPPLY CHAIN IMPACT ON THE MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET
4.3.1 OVERVIEW
4.3.2 RAW MATERIAL AVAILABILITY
4.3.3 MANUFACTURING CAPACITY
4.3.4 LOGISTICS AND LAST-MILE HURDLES
4.3.5 PRICING MODELS AND MARKET POSITIONING
4.4 INNOVATION STRATEGIES
4.4.1 KEY INNOVATION STRATEGIES
4.4.2 EMERGING DELIVERY TECHNIQUES
4.4.3 STRATEGIC IMPLICATIONS
4.4.4 CONCLUSION
4.5 RISK AND MITIGATION
4.6 VENDOR SELECTION DYNAMICS
4.6.1 PRODUCT QUALITY AND REGULATORY COMPLIANCE
4.6.2 SUPPLY CHAIN CAPABILITIES AND RELIABILITY
4.6.3 CLINICAL EFFICACY AND INNOVATION
4.6.4 COST COMPETITIVENESS AND REIMBURSEMENT COMPATIBILITY
4.6.5 LOCAL MARKET PRESENCE AND SUPPORT INFRASTRUCTURE
4.6.6 ETHICAL SOURCING, ESG COMPLIANCE, AND TRANSPARENCY
4.6.7 CONCLUSION
4.7 TARIFFS AND THEIR IMPACT ON MARKET
4.7.1 CURRENT TARIFF RATES IN TOP-5 COUNTRY MARKETS
4.7.2 OUTLOOK: LOCAL PRODUCTION V/S IMPORT RELIANCE
4.7.3 VENDOR SELECTION CRITERIA DYNAMICS
4.7.4 IMPACT ON SUPPLY CHAIN
4.7.5 IMPACT ON PRICES
4.7.6 REGULATORY INCLINATION
4.7.6.1 GCC TRADE ALIGNMENT & FTAS
4.7.6.2 SPECIAL ZONES AND RE-EXPORT MODELS
4.7.6.3 LOCAL SUBSIDY & POLICY RESPONSE
4.7.6.4 DOMESTIC COURSE OF CORRECTION
5 REGULATION COVERAGE
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING PREVALENCE OF RARE AND CHRONIC DISEASES
6.1.2 EXPANDING GERIATRIC POPULATION
6.1.3 TECHNOLOGICAL ADVANCEMENTS IN PLASMA FRACTIONATION
6.1.4 GOVERNMENT AND INSTITUTIONAL SUPPORT
6.2 RESTRAINTS
6.2.1 HIGH COST AND COMPLEX MANUFACTURING PROCESS
6.2.2 LACK OF PLASMA SUPPLY AND DONOR
6.3 OPPORTUNITIES
6.3.1 ADVANCEMENTS IN PLASMA PROCESSING TECHNOLOGIES TO ENHANCE YIELD AND REDUCE COSTS
6.3.2 REIMBURSEMENT FRAMEWORKS AND INCREASED GOVERNMENTAL FOCUS ON RARE DISEASE TREATMENT
6.3.3 STRATEGIC ALLIANCES, MERGERS, AND ACQUISITIONS TO STRENGTHEN MIDDLE EAST AND AFRICA MARKET PENETRATION
6.4 CHALLENGES
6.4.1 COMPETITIVE PRESSURE FROM RECOMBINANT AND ALTERNATIVE BIOLOGICAL THERAPIES
6.4.2 INFRASTRUCTURE LIMITATIONS IN COLD CHAIN LOGISTICS IMPACTING PRODUCT DISTRIBUTION
7 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT
7.1 OVERVIEW
7.2 IMMUNOGLOBULINS
7.3 COAGULATION FACTORS (FOR BLEEDING DISORDERS)
7.4 ALBUMIN (PLASMA VOLUME EXPANDER)
7.5 PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES)
7.6 MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS)
7.7 OTHER PLASMA DERIVED PROTEINS
8 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION
8.1 OVERVIEW
8.2 IMMUNOLOGY
8.3 HEMATOLOGY
8.4 CRITICAL CARE
8.5 NEUROLOGY
8.6 PULMONOLOGY
8.7 HAEMATO-ONCOLOGY
8.8 RHEUMATOLOGY
8.9 OTHER APPLICATIONS
9 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TECHNOLOGY
9.1 OVERVIEW
9.2 ION EXCHANGE CHROMATOGRAPHY
9.3 AFFINITY CHROMATOGRAPHY
9.4 CRYOPRECIPITATION
9.5 ULTRAFILTRATION
9.6 MICROFILTRATION
10 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE
10.1 OVERVIEW
10.2 MODERN
10.3 TRADITIONAL PLASMA FRACTIONATION
11 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS & CLINICS
11.3 RESEARCH LABS
11.4 ACADEMIC INSTITUTES
11.5 OTHERS
12 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 DIRECT TENDERS
12.3 THIRD PARTY DISTRIBUTORS
12.4 OTHERS
13 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION
13.1 MIDDLE EAST AND AFRICA
13.1.1 SOUTH AFRICA
13.1.2 SAUDI ARABIA
13.1.3 U.A.E.
13.1.4 ISRAEL
13.1.5 EGYPT
13.1.6 BAHRAIN
13.1.7 KUWAIT
13.1.8 OMAN
13.1.9 QATAR
13.1.10 REST OF MIDDLE EAST AND AFRICA
14 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 CSL
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENTS
16.2 TAKEDA PHARMACEUTICAL COMPANY LIMITED
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENTS
16.3 GRIFOLS, S.A.
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENTS
16.4 OCTAPHARMA AG
16.4.1 COMPANY SNAPSHOT
16.4.2 COMPANY SHARE ANALYSIS
16.4.3 PRODUCT PORTFOLIO
16.4.4 RECENT DEVELOPMENTS
16.5 KEDRION
16.5.1 COMPANY SNAPSHOT
16.5.2 COMPANY SHARE ANALYSIS
16.5.3 PRODUCT PORTFOLIO
16.5.4 RECENT DEVELOPMENT
16.6 ADMA BIOLOGICS, INC
16.6.1 COMPANY SNAPSHOT
16.6.2 REVENUE ANALYSIS
16.6.3 PRODUCT PORTFOLIO
16.6.4 RECENT DEVELOPMENT
16.7 AEGROS
16.7.1 COMPANY SNAPSHOT
16.7.2 PRODUCT PORTFOLIO
16.7.3 RECENT DEVELOPMENT
16.8 BHARAT SERUMS
16.8.1 COMPANY SNAPSHOT
16.8.2 PRODUCT PORTFOLIO
16.8.3 RECENT DEVELOPMENT
16.9 BIOTEST AG.
16.9.1 COMPANY SNAPSHOT
16.9.2 REVENUE ANALYSIS
16.9.3 PRODUCT PORTFOLIO
16.9.4 RECENT DEVELOPMENTS
16.1 FRESENIUS KABI AG
16.10.1 COMPANY SNAPSHOT
16.10.2 PRODUCT PORTFOLIO
16.10.3 RECENT DEVELOPMENT
16.11 GC BIOPHARMA CORPORATE
16.11.1 COMPANY SNAPSHOT
16.11.2 REVENUE ANALYSIS
16.11.3 PRODUCT PORTFOLIO
16.11.4 RECENT DEVELOPMENT
16.12 ICHOR
16.12.1 COMPANY SNAPSHOT
16.12.2 PRODUCT PORTFOLIO
16.12.3 RECENT DEVELOPMENT
16.13 INTAS PHARMACEUTICALS LTD.
16.13.1 COMPANY SNAPSHOT
16.13.2 PRODUCT PORTFOLIO
16.13.3 RECENT DEVELOPMENT
16.14 KAMADA PHARMACEUTICALS
16.14.1 COMPANY SNAPSHOT
16.14.2 REVENUE ANALYSIS
16.14.3 PRODUCT PORTFOLIO
16.14.4 RECENT DEVELOPMENT
16.15 KM BIOLOGICS
16.15.1 COMPANY SNAPSHOT
16.15.2 PRODUCT PORTFOLIO
16.15.3 RECENT DEVELOPMENT
16.16 LFB
16.16.1 COMPANY SNAPSHOT
16.16.2 PRODUCT PORTFOLIO
16.16.3 RECENT DEVELOPMENT
16.17 PLASMAGEN BIOSCIENCES PVT. LTD.
16.17.1 COMPANY SNAPSHOT
16.17.2 PRODUCT PORTFOLIO
16.17.3 RECENT DEVELOPMENTS
16.18 PROLIANT HEALTH & BIOLOGICALS
16.18.1 COMPANY SNAPSHOT
16.18.2 PRODUCT PORTFOLIO
16.18.3 RECENT DEVELOPMENT
16.19 PROMEA
16.19.1 COMPANY SNAPSHOT
16.19.2 PRODUCT PORTFOLIO
16.19.3 RECENT DEVELOPMENT
16.2 RELIANCE LIFE SCIENCES
16.20.1 COMPANY SNAPSHOT
16.20.2 BUSINESS PORTFOLIO
16.20.3 RECENT DEVELOPMENT
16.21 SICHUAN YUANDA SHYUANG PHARMACEUTICAL CO., LTD.
16.21.1 COMPANY SNAPSHOT
16.21.2 PRODUCT PORTFOLIO
16.21.3 RECENT DEVELOPMENT
16.22 SK PLASMA
16.22.1 COMPANY SNAPSHOT
16.22.2 PRODUCT PORTFOLIO
16.22.3 RECENT DEVELOPMENT
16.23 SYNTHAVERSE S. A.
16.23.1 COMPANY SNAPSHOT
16.23.2 REVENUE ANALYSIS
16.23.3 PRODUCT PORTFOLIO
16.23.4 RECENT DEVELOPMENTS
16.24 TAIBANG BIO GROUP CO., LTD
16.24.1 COMPANY SNAPSHOT
16.24.2 PRODUCT PORTFOLIO
16.24.3 RECENT DEVELOPMENT
16.25 VIRCHOW BIOTECH
16.25.1 COMPANY SNAPSHOT
16.25.2 PRODUCT PORTFOLIO
16.25.3 RECENT DEVELOPMENT
17 QUESTIONNAIRE
18 RELATED REPORTS
표 목록
TABLE 1 REGULATORY FRAMEWORK AND GUIDELINES
TABLE 2 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 3 MIDDLE EAST AND AFRICA IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 4 MIDDLE EAST AND AFRICA IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 5 MIDDLE EAST AND AFRICA INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 6 MIDDLE EAST AND AFRICA INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 7 MIDDLE EAST AND AFRICA COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 8 MIDDLE EAST AND AFRICA COAGULATION FACTORS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 9 MIDDLE EAST AND AFRICA FACTOR IX IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 10 MIDDLE EAST AND AFRICA RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 11 MIDDLE EAST AND AFRICA FACTOR VIII IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 12 MIDDLE EAST AND AFRICA RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 13 MIDDLE EAST AND AFRICA FIBRINOGEN IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 14 MIDDLE EAST AND AFRICA PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 15 MIDDLE EAST AND AFRICA VON WILLEBRAND FACTOR (VWF) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 16 MIDDLE EAST AND AFRICA FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 17 MIDDLE EAST AND AFRICA FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 18 IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 19 MIDDLE EAST AND AFRICA ALBUMIN IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 20 MIDDLE EAST AND AFRICA PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES)IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 21 MIDDLE EAST AND AFRICA PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 22 MIDDLE EAST AND AFRICA ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 23 MIDDLE EAST AND AFRICA C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 24 MIDDLE EAST AND AFRICA MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS )IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 25 MIDDLE EAST AND AFRICA MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 26 MIDDLE EAST AND AFRICA OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 27 MIDDLE EAST AND AFRICA OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 28 MIDDLE EAST AND AFRICA ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 29 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2025-2032 (USD THOUSAND)
TABLE 30 MIDDLE EAST AND AFRICA IMMUNOLOGY IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 31 MIDDLE EAST AND AFRICA HEMATOLOGY IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 32 MIDDLE EAST AND AFRICA CRITICAL CARE IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 33 MIDDLE EAST AND AFRICA NEUROLOGY IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 34 MIDDLE EAST AND AFRICA PULMONOLOGY IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 35 MIDDLE EAST AND AFRICA HEMATOLOGY -ONCOLOGY IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 36 MIDDLE EAST AND AFRICA RHEUMATOLOGY IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 37 MIDDLE EAST AND AFRICA OTHER APPLICATIONS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 38 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TECHNOLOGY, 2025-2032 (USD THOUSAND)
TABLE 39 MIDDLE EAST AND AFRICA ION EXCHANGE CHROMATOGRAPHY IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 40 MIDDLE EAST AND AFRICA AFFINITY CHROMATOGRAPHY IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 41 MIDDLE EAST AND AFRICA CRYOPRECIPITATION IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 42 MIDDLE EAST AND AFRICA ULTRAFILTRATION IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 43 MIDDLE EAST AND AFRICA MICROFILTRATION IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 44 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2025-2032 (USD THOUSAND)
TABLE 45 MIDDLE EAST AND AFRICA MODERN IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 46 MIDDLE EAST AND AFRICA TRADITIONAL PLASMA FRACTIONATION IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 47 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2025-2032 (USD THOUSAND)
TABLE 48 MIDDLE EAST AND AFRICA HOSPITALS & CLINICS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 49 MIDDLE EAST AND AFRICA RESEARCH LABS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 50 MIDDLE EAST AND AFRICA ACADEMIC INSTITUTES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 51 MIDDLE EAST AND AFRICA OTHERS BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 52 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2025-2032 (USD THOUSAND)
TABLE 53 MIDDLE EAST AND AFRICA DIRECT TENDERS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 54 MIDDLE EAST AND AFRICA THIRD PARTY DISTRIBUTORS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 55 MIDDLE EAST AND AFRICA OTHERS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 56 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 57 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 58 MIDDLE EAST AND AFRICA IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 59 MIDDLE EAST AND AFRICA INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 60 MIDDLE EAST AND AFRICA INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 61 MIDDLE EAST AND AFRICA COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 62 MIDDLE EAST AND AFRICA FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 63 MIDDLE EAST AND AFRICA RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 64 MIDDLE EAST AND AFRICA FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 65 MIDDLE EAST AND AFRICA RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 66 MIDDLE EAST AND AFRICA FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 67 MIDDLE EAST AND AFRICA PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 68 MIDDLE EAST AND AFRICA VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 69 MIDDLE EAST AND AFRICA FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 70 MIDDLE EAST AND AFRICA FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 71 MIDDLE EAST AND AFRICA ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 72 MIDDLE EAST AND AFRICA PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 73 MIDDLE EAST AND AFRICA ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 74 MIDDLE EAST AND AFRICA C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 75 MIDDLE EAST AND AFRICA MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 76 MIDDLE EAST AND AFRICA OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 77 MIDDLE EAST AND AFRICA ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 78 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 79 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)
TABLE 80 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)
TABLE 81 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 82 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 83 SOUTH AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 84 SOUTH AFRICA IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 85 SOUTH AFRICA INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 86 SOUTH AFRICA INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 87 SOUTH AFRICA COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 88 SOUTH AFRICA FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 89 SOUTH AFRICA RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 90 SOUTH AFRICA FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 91 SOUTH AFRICA RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 92 SOUTH AFRICA FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 93 SOUTH AFRICA PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 94 SOUTH AFRICA VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 95 SOUTH AFRICA FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 96 SOUTH AFRICA FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 97 SOUTH AFRICA ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 98 SOUTH AFRICA PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 99 SOUTH AFRICA ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 100 SOUTH AFRICA C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 101 SOUTH AFRICA MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 102 SOUTH AFRICA OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 103 SOUTH AFRICA ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 104 SOUTH AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 105 SOUTH AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)
TABLE 106 SOUTH AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)
TABLE 107 SOUTH AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 108 SOUTH AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 109 SAUDI ARABIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 110 SAUDI ARABIA IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 111 SAUDI ARABIA INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 112 SAUDI ARABIA INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 113 SAUDI ARABIA COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 114 SAUDI ARABIA FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 115 SAUDI ARABIA RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 116 SAUDI ARABIA FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 117 SAUDI ARABIA RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 118 SAUDI ARABIA FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 119 SAUDI ARABIA PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 120 SAUDI ARABIA VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 121 SAUDI ARABIA FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 122 SAUDIA ARABIA FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 123 SAUDI ARABIA ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 124 SAUDI ARABIA PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 125 SAUDI ARABIA ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 126 SAUDI ARABIA C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 127 SAUDI ARABIA MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 128 SAUDI ARABIA OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 129 SAUDI ARABIA ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 130 SAUDI ARABIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 131 SAUDI ARABIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)
TABLE 132 SAUDI ARABIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)
TABLE 133 SAUDI ARABIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 134 SAUDI ARABIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 135 U.A.E. BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 136 U.A.E. IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 137 U.A.E. INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 138 U.A.E. INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 139 U.A.E. COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 140 U.A.E. FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 141 U.A.E. RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 142 U.A.E. FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 143 U.A.E. RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 144 U.A.E. FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 145 U.A.E. PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 146 U.A.E. VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 147 U.A.E. FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 148 U.A.E. FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 149 U.A.E ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 150 U.A.E. PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 151 U.A.E. ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 152 U.A.E. C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 153 U.A.E MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 154 U.A.E. OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 155 U.A.E. ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 156 U.A.E. BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 157 U.A.E. BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)
TABLE 158 U.A.E. BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)
TABLE 159 U.A.E. BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 160 U.A.E. BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 161 ISRAEL BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 162 ISRAEL IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 163 ISRAEL INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 164 ISRAEL INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 165 ISRAEL COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 166 ISRAEL FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 167 ISRAEL RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 168 ISRAEL FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 169 ISRAEL RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 170 ISRAEL FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 171 ISRAEL PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 172 ISRAEL VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 173 ISRAEL FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 174 ISRAEL FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 175 ISRAEL ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 176 ISRAEL PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 177 ISRAEL ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 178 ISRAEL C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 179 ISRAEL MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 180 ISRAEL OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 181 ISRAEL ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 182 ISRAEL BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 183 ISRAEL BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)
TABLE 184 ISRAEL BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)
TABLE 185 ISRAEL BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 186 ISRAEL BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 187 EGYPT BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 188 EGYPT IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 189 EGYPT INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 190 EGYPT INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 191 EGYPT COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 192 EGYPT FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 193 EGYPT RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 194 EGYPT FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 195 EGYPT RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 196 EGYPT FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 197 EGYPT PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 198 EGYPT VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 199 EGYPT FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 200 EGYPT FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 201 EGYPT ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 202 EGYPT PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 203 EGYPT ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 204 EGYPT C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 205 EGYPT MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 206 EGYPT OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 207 EGYPT ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 208 EGYPT BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 209 EGYPT BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)
TABLE 210 EGYPT BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)
TABLE 211 EGYPT BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 212 EGYPT BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 213 BAHRAIN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 214 BAHRAIN IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 215 BAHRAIN INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 216 BAHRAIN INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 217 BAHRAIN COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 218 BAHRAIN FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 219 BAHRAIN RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 220 BAHRAIN FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 221 BAHRAIN RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 222 BAHRAIN FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 223 BAHRAIN PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 224 BAHRAIN VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 225 BAHRAIN FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 226 BAHRAIN FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 227 BAHRAIN ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 228 BAHRAIN PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 229 BAHRAIN ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 230 BAHRAIN C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 231 BAHRAIN MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 232 BAHRAIN OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 233 BAHRAIN ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 234 BAHRAIN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 235 BAHRAIN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)
TABLE 236 BAHRAIN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)
TABLE 237 BAHRAIN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 238 BAHRAIN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 239 KUWAIT BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 240 KUWAIT IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 241 KUWAIT INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 242 KUWAIT INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 243 KUWAIT COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 244 KUWAIT FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 245 KUWAIT RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 246 KUWAIT FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 247 KUWAIT RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 248 KUWAIT FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 249 KUWAIT PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 250 KUWAIT VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 251 KUWAIT FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 252 KUWAIT FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 253 KUWAIT ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 254 KUWAIT PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 255 KUWAIT ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 256 KUWAIT C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 257 KUWAIT MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 258 KUWAIT OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 259 KUWAIT ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 260 KUWAIT BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 261 KUWAIT BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)
TABLE 262 KUWAIT BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)
TABLE 263 KUWAIT BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 264 KUWAIT BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 265 OMAN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 266 OMAN IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 267 OMAN INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 268 OMAN INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 269 OMAN COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 270 OMAN FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 271 OMAN RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 272 OMAN FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 273 OMAN RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 274 OMAN FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 275 OMAN PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 276 OMAN VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 277 OMAN FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 278 OMAN FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 279 OMAN ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 280 OMAN PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 281 OMAN ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 282 OMAN C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 283 OMAN MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 284 OMAN OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 285 OMAN ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 286 OMAN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 287 OMAN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)
TABLE 288 OMAN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)
TABLE 289 OMAN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 290 OMAN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 291 QATAR BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 292 QATAR IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 293 QATAR INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 294 QATAR INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 295 QATAR COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 296 QATAR FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 297 QATAR RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 298 QATAR FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 299 QATAR RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 300 QATAR FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 301 QATAR PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 302 QATAR VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 303 QATAR FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 304 QATAR FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 305 QATAR ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 306 QATAR PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 307 QATAR ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 308 QATAR C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 309 QATAR MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 310 QATAR OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 311 QATAR ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 312 QATAR BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 313 QATAR BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)
TABLE 314 QATAR BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)
TABLE 315 QATAR BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 316 QATAR BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 317 REST OF MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
그림 목록
FIGURE 1 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: MULTIVARIATE MODELLING
FIGURE 7 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: MARKET END USER COVERAGE GRID
FIGURE 10 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: SEGMENTATION
FIGURE 12 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT (2024)
FIGURE 13 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: EXECUTIVE SUMMARY
FIGURE 14 STRATEGIC DECISIONS
FIGURE 15 RISING PREVALENCE OF RARE AND CHRONIC DISEASES IS EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET IN THE FORECAST PERIOD OF 2025 TO 2032
FIGURE 16 IMMUNOGLOBULINS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET IN THE FORECAST PERIOD OF 2025 & 2032
FIGURE 17 PORTER’S FIVE FORCES
FIGURE 18 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES FOR THE MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET
FIGURE 19 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY PRODUCT, 2024
FIGURE 20 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY PRODUCT, 2025-2032 (USD THOUSAND)
FIGURE 21 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY PRODUCT, CAGR (2025-2032) (2025-2032)
FIGURE 22 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 23 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY APPLICATION, 2024
FIGURE 24 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY APPLICATION, 2025-2032 (USD THOUSAND)
FIGURE 25 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY APPLICATION, CAGR (2025-2032) (2025-2032)
FIGURE 26 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 27 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY TECHNOLOGY, 2024
FIGURE 28 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY TECHNOLOGY, 2025-2032 (USD THOUSAND)
FIGURE 29 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY TECHNOLOGY, CAGR (2025-2032) (2025-2032)
FIGURE 30 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 31 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY MODE, 2024
FIGURE 32 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY MODE, 2025-2032 (USD THOUSAND)
FIGURE 33 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY MODE, CAGR (2025-2032) (2025-2032)
FIGURE 34 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY MODE, LIFELINE CURVE
FIGURE 35 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY END USER, 2024
FIGURE 36 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY END USER, 2025-2032 (USD THOUSAND)
FIGURE 37 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY END USER, CAGR (2025-2032) (2025-2032)
FIGURE 38 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY END USER, LIFELINE CURVE
FIGURE 39 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY DISTRIBUTION CHANNEL, 2024
FIGURE 40 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY DISTRIBUTION CHANNEL, 2025-2032 (USD THOUSAND)
FIGURE 41 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2025-2032) (2025-2032)
FIGURE 42 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 43 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: SNAPSHOT (2024)
FIGURE 44 MIDDLE EAST AND AFRICA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: COMPANY SHARE 2024 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.
